News & Updates

Twelve-month treatment with zoledronate significantly increases bone mineral density (BMD) Z-scores without affecting growth in nonambulant children with cerebral palsy (CP), reports a study. However, side effects of the first dose are common.

Serum levels of remnant cholesterol may be used to assess an individual’s susceptibility to developing nonalcoholic fatty liver disease (NAFLD), independent of traditional lipid profiles, suggests a recent study.

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Metformin treatment discontinuation has been found to lead to increased incidence of dementia among older adults, and this association cannot be explained by changes in glucose control or insulin use.

Treatment with lepodisiran yields dose-dependent and durable reductions in serum lipoprotein(a) levels while being well tolerated, according to the results of a phase I trial.

The novel potassium binder, sodium zirconium cyclosilicate, has proven to be safe and effective for lowering potassium levels in the blood of Asian patients undergoing maintenance haemodialysis (HD) treatments, as shown in a study from Singapore.

New drug applications approved by US FDA as of 01-15 November  2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Frequently adding salt to foods increases not only the risk of hypertension but the risk of type 2 diabetes (T2D) as well, as reported in a large study.